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Abstract
Approaches to knowledge extraction (KE) in
the health domain often start by annotating text
to indicate the knowledge to be extracted, and
then use the annotated text to train systems to
perform the KE. This may work for annotat-
ing named entities or other contiguous noun
phrases (drugs, some drug effects), but be-
comes increasingly difficult when items tend
to be expressed across multiple, possibly non-
contiguous, syntactic constituents (e.g. most
descriptions of drug effects in user-generated
text). Other issues include that it is not al-
ways clear how annotations map to actionable
insights, or how they scale up to, or can form
part of, more complex KE tasks. This paper
reports our efforts in developing an approach
to extracting knowledge about drug nonadher-
ence from health forums which led us to con-
clude that development cannot proceed in sep-
arate steps but that all aspects—from concep-
tualisation to annotation scheme development,
annotation, KE system training and knowl-
edge graph instantiation—are interdependent
and need to be co-developed. Our aim in this
paper is two-fold: we describe a generally ap-
plicable framework for developing a KE ap-
proach, and present a specific KE approach,
developed with the framework, for the task
of gathering information about antidepressant
drug nonadherence. We report the conceptual-
isation, the annotation scheme, the annotated
corpus, and an analysis of annotated texts.
1 Introduction
Depression is experienced by 1 in 4 people in the
UK. More than two thirds of patients are mostly
managed with antidepressant medication, yet non-
adherence rates are very high. One study found
that 4.2% of patients who were prescribed antide-
pressants did not take them at all, and 23.7% filled
only a single prescription (van Geffen et al., 2009).
Nonadherence is a major obstacle in the effective
treatment of depression, but cannot currently be
predicted or explained adequately (van Dulmen
et al., 2007). An influential WHO report (Sabate´
et al., 2003) concluded: “[i]ncreasing the effec-
tiveness of adherence interventions may have a far
greater impact on the health of the population than
any improvement in specific medical treatments”.
Nonadherence is hard to investigate via controlled
studies meaning alternative sources of information
are needed. Recent results indicate a strong sig-
nal relating to usage of psychiatric medications on
health forums and social media (Tregunno, 2017),
and that social media users report nonadherence
and reasons for it (Onishi et al., 2018).
The work reported in this paper aimed (i) to de-
velop a conceptualisation of the information space
around drug nonadherence, defining the relevant
concepts, properties and relations; (ii) to develop
an annotation scheme based on the conceptualisa-
tion; (iii) to annotate a corpus of depression health
forum posts with the scheme; and (iv) to use the
annotated data to examine the prevalence, and co-
occurrence, of different kinds of nonadherence in-
formation (testing signal strength). We examine
the interdependent and mutually constraining re-
lationship between conceptualisation, annotation
scheme and knowledge extraction processes.
The ultimate goal is to perform automatic
knowledge extraction (KE) in order to provide
valuable non-adherence information from a large
sample about why and how non-adherence occurs.
We hope this will in turn lead to better prescribing,
better adherence and more informed discussions
between patient and prescriber around medication.
2 Nonadherence and Health Forums
Different terms have been used to describe the
“suboptimal taking of medicine by patients”
(Hugtenburg et al., 2013). Among these, non-
compliance and nonadherence both mean not tak-
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Quitting your meds can be awful, for sure. I started trying to get off Zoloft by myself 5 years ago. I went cold
turkey which was a complete disaster. Next I tried cutting down by large amounts which was slightly less of a
disaster. Finally I tapered off very slowly. ONE WHOLE YEAR to get from 200mg to zero. With the tapering off
the brain zaps were much less severe. Simply takes a long time to wean yourself off these drugs.
I reduced my mirtazapine from 45mg first to 30mg, and then to 15mg, then stopped it altogether. After two weeks
I was feeling awful so I decided to restart it at 15mg.
So I stopped Fluoxetine about a month ago sort of by accident. After I missed a few doses I just decided to keep
going. So far I’ve only had rather minor symptoms. One of my symptoms has been an electric shock sensation
from my brain down my spine/body. This happens especially when I get up, sit down or move suddenly.
Last week my doctor increased my Lamictol dosage to 200 MG. I am beginning to notice serious cognitive deficits.
For example constantly losing/misplacing things.. Has anyone else experienced this situation?
Figure 1: Four example depression forum posts created to closely resemble real posts.
ing a drug as instructed (the intended meaning
in the present context), but nonadherence is the
term now preferred as reflecting a more equal
prescriber-patient relationship (Hugtenburg et al.,
2013). Two types of nonadherence are distin-
guished, intentional, where a patient “actively de-
cides” not to follow instructions, and unintentional
nonadherence, including forgetting and not know-
ing how to take a drug (Hugtenburg et al., 2013).
Consider the four example posts from health
forums for specific antidepressants in Figure 1.
Some of the sentences contain explicit statements
that the modifications described were instigated by
the patient (“I started trying to get off Zoloft by
myself 5 years ago”; “After two weeks I was feel-
ing awful so I decided to restart it at 15mg”; “So
I stopped Fluoxetine about a month ago sort of by
accident”). Other modifications described in the
first three posts (unlike in the fourth) are likely to
also have been instigated by the patient, but clini-
cian involvement cannot be ruled out.
These are typical examples of how patients talk
about nonadherence in health forums: explicit
statements (‘my doctor told me to do one thing,
but I did another’) are rare (7% of posts on the
depression forums we have been looking at, see
also Section 5). More typically, a drug modifica-
tion is described along with the side effect and/or
other reason(s) that gave rise to it, but the extent to
which the prescribing physician was involved in
deciding to make the modification can only be in-
ferred, with varying degrees of certainty, from the
language, or on the basis of medical knowledge
(e.g. a modification is known to be dangerous).
3 Conceptualisation and KE Task
Posts like the ones in Figure 1 clearly contain in-
formation about the why and how of drug nonad-
herence, but how can it be automatically extracted
and rendered useful? In this section we discuss
the main issues in developing a knowledge extrac-
tion (KE) approach for a specific domain and a
specific KE task, nonadherence event extraction in
our case. To introduce the different components in
developing an approach to KE (overview see Fig-
ure 2, we use as an illustrative running example the
simpler task of drug effect extraction which is—in
contrast to the far more complex task of nonad-
herent event extraction we are addressing here—
already a well established research task1 (Leaman
et al., 2010; Nikfarjam et al., 2015). Drug effect
detection is an important subtask of nonadherence
event extraction, because drug effects as perceived
by the patient play an important role in nonadher-
ence and are often the reason for it. The last post in
Figure 1 is a typical example, containing a claim
that a drug referred to as “Lamictol”, is causing an
effect described as “cognitive deficits”.
3.1 From Text to Meaning
Suppose that we have a method capable of iden-
tifying drug and effect mentions in text and de-
termining which ones are linked (i.e. which drug
causes which effect), and that we extract a linked
drug and effect pair from the fourth post in Fig-
ure 1 for which we could choose the following
notation: cause(“Lamictol”,“cognitive deficits”).
Suppose from this and other posts we extract five
such linked pairs as follows:
cause(“Lamictol”,“serious cognitive deficits”)
cause(“Lamictol”,“constantly losing/misplacing
things”)
cause(“Lamictal”,”uncoordinated”)
cause(“lamotrigine”,”so forgetful”)
cause(“Lamotrigene”,”keep losing my phone and
going upstairs and forgetting what for”)
(1)
1See e.g. Task 2 at this year’s SMM4H Shared Task event:
https://healthlanguageprocessing.org/smm4h/challenge/
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If this was the actual output of our method, it
would be nothing more than a list of drug-effect
mentions in a given set of texts, possibly with
counts of multiple occurrences of identical men-
tions (none in Example 1 above). One important
type of knowledge would be entirely inaccessible,
namely that the above five pairs in fact all claim
the same side effect for the same drug (lamot-
rigine, a mood-stabilising medication sometimes
prescribed for depression).2 In order to extract
that knowledge (crucial to be able e.g. to act upon
side effect reports depending on novelty or report
frequency), the identified word strings need to be
mapped to a more abstract level of representation
where knowledge is encoded in terms of concepts,
rather than word strings. It is only once this pro-
cess, known as entity linking3 (Han et al., 2011;
Hachey et al., 2013; Rao et al., 2013; Smith et al.,
2018), has been performed that the five linked
pairs above can be interpreted as five mentions of
the same drug effect. In this crucial step, we move
from extracting word strings (surface representa-
tions) to extracting concept structures (meaning
representations); from something that can be com-
pared in terms of string similarity and counted, to
something that can be incorporated into a knowl-
edge graph and reasoned about.
3.2 Concept Model and KE Template
In the case of drug effect extraction it is clear
what we want to extract, and how it is struc-
tured. A very simple conceptualisation suffices to
express that understanding: a single parent con-
cept, drug effect, consisting of a drug, an effect
and a causal relation, possibly implicit. Depend-
ing on application context, further concepts, such
as duration or severity, could also be added (these
would be required e.g. if the application task was
automatic completion of Yellow Card reports).
One of many possible notations for this conceptu-
alisation is the following (for a complete concept
model the range of possible values of the compo-
nent concepts would also have to specified):
DRUG EFFECT [DRUG; EFFECT; SEVERITY; DURATION ] (2)
The above can be seen as providing both a concept
model representing a piece of domain knowledge,
2Whether they are considered the same depends on the
concept set linked to, in our case SIDER (Kuhn et al., 2015).
3A.k.a. normalisation, e.g. for adverse effect normalisa-
tion see Task 3 at this year’s SMM4H Shared Task event:
https://healthlanguageprocessing.org/sm m4h/challenge/
Figure 2: Components in developing KE approach.
and a template to be instantiated by a specific KE
tool (depending on the application task, only sub-
sets of concepts might be used for KE). A possible
instantiation produced by a KE tool via entity de-
tection and linking for the last post in Figure 1 is
the following (initial underscores indicating termi-
nal concepts as opposed to word strings):
DRUG EFFECT [
DRUG= lamotrigine;
EFFECT= confusional state;
SEVERITY= moderate;
DURATION= continuous; ]
(3)
In order to produce the above we have to have cre-
ated a suitable conceptualisation (concept model),
a KE template, a KE task construal and methods
for implementing it, here detecting word spans
corresponding to the above concepts and for map-
ping the word spans to concepts. In order to be
able to do the latter, we also need texts which have
been labelled for entities such as drugs and effects
and the links between them. All these aspects are
shown to the left of Figure 2 which provides an
overview of elements and steps involved in devel-
oping a KE approach. In the next sections we look
at how conceptualisation and annotation scheme
interact with possible KE tasks (Section 3.3), fol-
lowed by issues in determining the details of the
annotation scheme (Section 3.4).
3.3 Text Annotation and KE Task
Useful one-off analysis can be conducted on the
basis of manual mark-up of text, but for knowl-
edge extraction from large quantities of new texts,
automatic processes are needed. Two common
types of KE model are word sequence (post, sen-
tence, phrase, etc.) classifiers and labellers. These
tend to be supervised models, i.e. they require la-
belled training data the creation of which, espe-
cially initially, requires human annotation effort.
How the data is annotated limits what kind of
KE tasks and models it can be used for. Con-
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versely, aiming for a particular KE task has im-
plications for the kinds of annotations that are
needed. For the KE task described above, i.e.
mapping from health forum posts (Figure 1) to
instantiated KE templates (Example 3), the most
straightforward way to interpret the annotation
task would be to annotate each post (as a whole)
with an instantiated KE template for every men-
tion of a drug effect contained in the post. How-
ever, this would make the annotators’ task cog-
nitively extremely challenging (requiring multiple
judgments to be made in conjunction), and very
time-intensive (involving look up of concepts in
databases and inventories). Moreover, it is not ob-
vious how to define a corresponding KE modelling
task and training regime. It is also not feasible to
define one output class for each possible instanti-
ated template, because that would lead to an un-
manageable combinatorial explosion of classes.
In the relatively simple case of adverse drug ef-
fect extraction, the divide-and-conquer approach
that tends to be used instead (Nikfarjam et al.,
2015; Metke-Jimenez and Karimi, 2016) con-
strues the task, as mentioned above, as a sequence
of subtasks, first identifying all mentions of drugs
and effects in the text, then linking them to con-
cepts and to each other. For the first step to be pos-
sible, drug mentions and effect mentions need to
be identified in the text, for which corresponding
mark-up needs to be available in the training data.
Similarly, any links between the marked up enti-
ties also need to be present in the annotations. The
identified text strings can then be mapped (linked)
in a separate step to drug (e.g. lamictol) and ef-
fect (e.g. confusional state) concepts, potentially
with separately retrained off-the-shelf tools.
The above discussion points to an annotation
scheme involving a DRUG concept (but not con-
cepts for individual drugs), and an EFFECT con-
cept (but not concepts for specific effects), and for
corresponding labels to be inserted into texts as
mark up. However, more issues arise when map-
ping these conclusions to an annotation scheme.
3.4 Towards an Annotation Scheme
Some of the questions that arise in text annota-
tion are (1) whether conceptually grounded anno-
tations should attach to word strings (a) with the
meaning ‘these words together express the given
concept’, or (b) with the meaning ‘somewhere in
this text there is an occurrence of the concept’;
(2) whether labels should be (a) terminal concepts
(e.g. lamictol) or (b) classes of terminal concepts
(e.g. Drug); (3) how to treat instances where an
entity or event is mentioned, but is not asserted to
have occurred or have been observed, which hap-
pens e.g. with negation, questions or hypothetical
considerations; and (4) how to present the task to
annotators in such a way that the cognitive load is
within manageable limits and annotations can be
replicated with sufficient consistency.
Not all concepts can clearly and easily be asso-
ciated with specific words in the text. While men-
tions of a drug or effect entity always have cor-
responding words in the text (entity annotations
fall under (1a) above), this is not necessarily the
case of concepts naturally seen as relations be-
tween other concepts. Consider again the last post
in Figure 1: there are no substrings that can be as-
sociated with Lamictol causing cognitive deficits.
Rather, it is the first two sentences in their en-
tirety that imply (but do not state explicitly) the
causal link. It tends to be considered not appro-
priate to mark up such relations in text, and they
attach instead to one or more already marked up
word strings (meaning they fall under (1b) above).
Regarding (2) above, aside from the issues
raised in Section 3.3, available resources are a
deciding factor: e.g. it would take annotators far
longer to determine the specific drug concept la-
bel for a drug mention than it would to simply la-
bel each such mention with a generic drug label.
Regarding (3), while KE would typically aim
to extract information with factual status from text
(e.g. all drug effects patients claim to have expe-
rienced), far from all mentions of such informa-
tion have factual status (drug effect mentions an be
negated, part of a question, etc.). Simply treating
e.g. a negated drug effect as not a drug effect is un-
likely to be helpful in a machine learning context,
because negated and non-negated versions will
look identical except for a negation marker else-
where in the text, potentially resulting in a large
number of spurious negative examples. It is more
likely to help generalisation to treat all drug effect
mentions identically, and to additionally mark up
in annotations, and subsequently learn, the charac-
teristics of negation. The same holds for generali-
sations, questions and similar phenomena.
Regarding (4), it is virtually impossible to
achieve perfect consistency between annotators,
or even self-consistency, with mark-up annotation
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DRUG NONADHERENCE [
+DRUG MODIFICATION [ instigated by = patient
intentional || patient unintentional ] ]
DRUG MODIFICATION [
drug : Drugs
change : DOSE CHANGE || FORM CHANGE || PROD
UCT CHANGE
+reason : DRUG EFFECT || DRUG PROPERTY ||
Other Reason
instigated by : Instigator
+mod effect : EFFECT || Other Outcome ]
DOSE CHANGE [
?from dose : ( Numbers, Units, Time Span )
?to dose : ( Numbers, Units, Time Span )
dose mod type : DoseModTypes ]
FORM CHANGE [
?from form : Form Types
?to form : Form Types ]
PRODUCT CHANGE [
?from product : Drug Products
?to product : Drug Products ]
DRUG EFFECT [
drug : Drugs
medDRA preferred term : MPTs
duration : ( Numbers, Units )
severity : Severity Levels ]
DRUG PROPERTY [
drug : Drugs
property : Drug Properties ]
Drugs = {x|x is a drug entry in SIDER}
Drug Products = {x|x is a drug product entry in SIDER}
MPTs = {x|x is an MPT entry in SIDER}
Drug Properties = { effective, ineffective, like, dis-
like, cheap, expensive, ...}
Numbers = {x|x ∈ IR}
Units = { ml, mg, ...}
Time Span = { halfday, day, week, ...}
Form Types = { tablet, powder, solution, cream, ...}
DoseModTypes = { start, stop, increase, decrease}
Other Reason = { life event, insurance financial,
view belief, ...}
Instigator = { patient intentional, patient unintentional,
clinician, both together, other}
Other Outcome = { negative, positive, neutral}
Severity Levels = { mild, moderate, severe}
Figure 3: Nonadherence concept model (UML-like no-
tation). + = 1 or more; || = xor; ? = at least 1 of two.
schemes. For simpler concepts corresponding to
fewer possible word strings, such as named enti-
ties of type drug, issues are comparatively simple,
and inter-annotator agreement (IAA, the extent to
which annotators agree where drug mentions be-
gin/end) would be high. As is apparent even in the
simple example word strings in Example 1, there
is comparatively higher variation in word strings
describing side effects: if the last two examples
were extracted from the longer strings I’m being
so forgetful and I just keep losing my phone..., re-
spectively, in our experience there tends to be con-
siderable variation among annotators about where
to place the start of the effect mention.
One way to address this is to ensure that the
concepts underlying annotation labels are highly
coherent and crisply defined, so that there is high
concurrence among annotators in how to interpret
and apply them. This underlines the need to co-
develop conceptualisation and annotation scheme,
because they provide the formal grounding that
can help ensure coherence and crispness. For high
IAA, the tasks annotators are asked to perform
need to be focused and homogeneous, and the vi-
sual interfaces as uncluttered as possible. If this is
not the case it can make the task too difficult, and
also quickly lead to frustration among annotators.
4 An Approach to Nonadherence KE
In this section, we scale up the insights from Sec-
tion 3 to an approach to knowledge extraction
(KE) in the nonadherence domain, a substantially
more complex task than drug effect detection. We
adopt the definition of nonadherence as not taking
a drug as instructed (Section 2), and assume that
the relationship between a patient and a drug starts
with a prescription and instructions issued by a
clinician. We see nonadherence as one or more
modifications to the original prescription regimen,
or to a previous modification, made without the
approval of the prescribing clinician. Our first task
then is to model the concept of modification, after
which we can define nonadherence as modifica-
tions instigated by the patient. Our goal is to de-
sign a concept model, KE template and annotation
scheme for nonadherence that support KE meth-
ods that extract information about the how and why
of drug nonadherence.
4.1 Concept Model
Information about how and why nonadherent drug
modifications occur will necessarily involve a spe-
cific drug. To address the how part, we need
to know what type of modification was carried
out. Nonadherent modifications in all examples
we have encountered involve some change to the
dose that is taken, if stopping, starting and forget-
ting to take a drug are considered dose modifica-
tions. Other types of modifications also apply to
drug form (tablet, capsule, etc.), or drug brand
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(e.g. generic vs. branded). To address the why part,
we also need to know the reason for the modifica-
tion and its effect, because it often becomes the
reason for a further modification. Our nonadher-
ence concept model is shown in Figure 3. Starting
from the top, it defines drug nonadherence as one
or more drug modifications instigated by the pa-
tient either intentially or unintentionally. A drug
modification is composed of a drug, a change, op-
tionally a reason and an effect, plus a specifica-
tion of instigation. A reason is either a drug effect,
drug property or another reason. A drug effect is
as defined in Section 3; a drug property identifies
the drug it relates to and covers non-effect proper-
ties such as cost, how well it works and whether
the patient likes it. Other reasons include reasons
relating to life events, insurance issues and beliefs
held by the patient. Others are possible, and as
indicated in the model, we have not defined a fi-
nal set of terminal concepts for some of the preter-
minals (preterminal concepts are indicated by ital-
ics). In order to define the possible terminal con-
cepts for the preterminal drugs, drug products and
effects concepts, we use the SIDER knowledge
base (Kuhn et al., 2015).
4.2 KE Template and Task
The concept model in Figure 3 is task-agnostic.
For the specific task of nonadherence event extrac-
tion from health forum posts it needs to be mapped
to a KE template, task specification and annotation
scheme that are necessarily task-specific. Follow-
ing inspection of about 200 random texts from our
corpus of 150K posts (Section 5), and based on
the concept model above, we construe the nonad-
herence KE task as follows:
1. Binary classification of posts into first person narration vs.
others.
2. Binary classification of posts into containing modification
mentions vs. others.
3. Anaphora resolution: replace drug, drug form and drug
dose anaphora with full references.
4. Entity detection: drug, dose, effect, modification.
5. Entity linking: drug, effect, modification (yielding modi-
fication type); text normalisation: dose.
6. Topic segmentation: drug related, other.
7. NE relation detection via binary classification (applied to
drug-related topic fields only):
• drug, dose, context→ dose of?
• drug, effect, context→ drug effect?
• dose, effect, context→ dose effect?
• modification, drug, context→ drug modification?
• modification, dose, context→ drug modification?
• drug modification, effect, context→ mod reason?
• drug modification, context→ clinician, patient in
tentional, patient unintentional, both together,
not stated?
• drug modification, context→ stop, start, increase,
decrease, unclear?
Note that we do not currently include product or
form changes in the task construal. Moreover, we
are leaving identification of drug properties, and
modification reasons other than effects to future
work. While the first six tasks above would need to
be implemented, in this order, in a pipeline, there
is no intention to imply that the subtasks under (7)
would be implemented separately and in a specific
order. Rather, there is likely to be benefit from
jointly modelling some or even all of them.
The above KE process is aimed at filling KE
templates derived from the concept model in Fig-
ure 3 (and the annotation scheme in the next sec-
tion). Initially, we are using the following tem-
plate for each drug modification identified by the
KE process, here instantiated for the second and
third sentences in the first post in Figure 1:
DRUG MODIFICATION [
DRUG= sertraline;
DOSE= unknown;
MOD REASON= unknown;
MOD TYPE= stop;
INSTIGATED BY= patient intentional; ]
(4)
Ideally we would also like to extract information
about the severity and duration of drug effects, and
the order in which they occur, but have had to ex-
clude those for the time being as infeasibly hard
from health forum posts.
4.3 Nonadherence Annotation Scheme
The annotation scheme we have devised to match
the concept model, KE task and KE template
above, consists of 8 entities and 3 events, as shown
in Figure 4. The entities are annotated as labels at-
tached to identified word strings in the text, with
the meaning of (1a) in Section 3.4. Events are not
associated with word spans, but link two or more
entities; events also have sets of attributes.
In order to minimise cognitive load for our
annotators, we made several implementational
choices that are not reflected in Figure 4, partly
influenced by the brat evaluation tool we are us-
ing for annotating texts.4 E.g. we annotated
DRUG EFFECT and DRUG PROPERTY events in one
round, and DRUG MODIFICATION events in another,
4brat.nlplab.org
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Entities:
Drug, Drugs, Drug Dose, Drug Form, Drug Brand, Drug Effect, Drug Property, Other Reason.
Events:
DRUG EFFECT:
Argument 1: (Drug|Drugs|Drug Form|Drug Dose|Drug Brand)+
Argument 2: Drug Effect.
Attributes (binary, optional): Question, Negation, Generalisation, Speculation, ReducedCertainty.
DRUG PROPERTY:
Argument 1: (Drug|Drugs|Drug Form|Drug Dose|Drug Brand)+
Argument 2: Drug Property
Attributes (binary, optional): Question, Negation, Generalisation, Speculation, ReducedCertainty.
DRUG MODIFICATION:
Argument 1: Drug|Drug Form|Drug Dose|Drug Brand
Argument 2 (reason(s) for modification): (DRUG EFFECT|DRUG PROPERTY|Other Reason)*
Attributes (binary, optional): Question, Negation, Generalisation, Speculation, ReducedCertainty.
Attributes (multiple valued, obligatory):
Instigated By = {not stated, clinician, patient intentional, patient unintentional, both together}.
Mod Type = {increase, decrease, start, stop, unclear}.
Relations:
antecedent: links pronouns and common noun references to their most recent antecedent (named reference).
dose of, form of, brand of: link dose, form and brand mentions to the drugs they relate to.
Figure 4: Nonadherence annotation scheme.
separate round; we annotated antecedent links as
chains of antecedent relations to the nearest full
reference, using all intervening anaphoric refer-
ences, in order to minimise clutter in the interface.
4.4 Agreement among annotators
The scheme was developed in several iterations of
development /testing, each time improving con-
cept model, scheme and Inter-Annotator Agree-
ment (InterAA). For annotations with the final ver-
sion of the scheme we allowed four hours per 50
posts (average post length is 83 words). InterAA
for entities, as measured by averaged brateval
scores (F1 on combined label/span matches) com-
puted on 50 random posts, between our two main
annotators, ranges from 0.74 for Drug Effect, and
0.64 for Drug, to 0.39 for Drug Property. The cor-
responding IntraAA scores are 0.85, 0.8 and 0.75
for one annotator, and 0.75, 0.73, and 0.81 for the
other (numbers for Drug Property indicate anno-
tators are interpreting the guidance differently).
5 Data Collection and Analysis
We opted for arms-length data scraping and de-
identification where a trusted third party scraped
health forum posts, and de-identified the texts,
making available to us the masked version of the
dataset only. The partner accessed and down-
loaded all posts on the 11 drug-specific forums on
www.depressionforums.org at the end of 20 Dec
2018, yielding 148,575 posts. The posts were pro-
cessed and converted to text-only form, forum post
IDs were removed and replaced with new dataset-
specific post IDs, and personally identifiable in-
formation (PII) was masked, e.g. usernames were
replaced by the token [USER] and person names
by [NAME]. In addition, the partner performed
adverse event (AE) (Nielsen, 2011) and sentiment
scoring (Xu and Painter, 2016) for each post. AE
scores express the probability p that the post con-
tains mention of an adverse event (AE), thresh-
olded at p=0.7. Sentiment scores range from -5 to
5, with negative sentiment thresholded at -1, and
positive sentiment at 1, with scores from -1 to 1
indicating neutral sentiment.
Post were distributed over the 11 forums as
shown in Table 1 in terms of number of posts
and percentage of total (columns 2 and 3); also
shown are median post length, percentage of posts
with AEs, and percentages of posts with posi-
tive/negative/neutral sentiment. Some trends can
be observed in Table 1. Post length tends to go up
as forum size increases. Some forums contain sub-
stantially higher rates of AE mentions than others:
prevalence ranges from 47.6% of posts for Abil-
ify, to 63.9% for Citalopram. These correlate to
some extent with sentiment scores: e.g. 22.5% of
Abilify posts were classified as negative in senti-
ment, compared to 28.1% for Citalopram. There
is no correlation (Pearsons r=0.17) between % AE
mention and % positive sentiment; there is a strong
inverse correlation (r=-0.74) between % AE and
% neutral sentiment, and some correlation (r=0.3)
between % AE and % negative sentiment.
We have so far annotated 2,000 posts in Phase 1.
In the annotated posts, there are 3,882 individual
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Forum Posts %-age Median % AE % pos % neg % neut
tokens mention sentim. sentim. sentim.
55-citalopram-celexa-lexapro-escitalopram 31,286 21.1% 87 63.9% 50.2% 21.7% 28.1%
46-other-depression-and-anxiety-medications 21,408 14.4% 80 56.3% 47.7% 24.7% 27.6%
56-wellbutrin-bupropion 20,098 13.5% 93.5 62.6% 51.0% 21.8% 27.2%
53-zoloftlustral-sertraline 19,597 13.2% 87 64.4% 50.2% 21.2% 28.5%
54-effexor-venlafaxine-pristiq-desvenlafaxine 15,014 10.1% 82 63.8% 46.5% 23.1% 30.4%
50-cymbalta-duloxetine 12,439 8.4% 85 62.1% 49.0% 22.0% 28.9%
52-prozac-fluoxetine 11,166 7.5% 80 54.3% 47.7% 23.2% 29.0%
51-remeron-mirtazapine 8,142 5.5% 80 61.4% 51.7% 22.6% 25.7%
57-paxilseroxat-paroxetine 4,476 3.0% 68 52.2% 45.9% 23.4% 30.7%
103-abilify-aripiprazole 3,223 2.2% 56 47.6% 52.2% 25.3% 22.5%
102-viibryd-vilazodone 1,726 1.2% 59 55.7% 42.9% 26.4% 30.7%
Total 148,575 100.0% 83 60.9% 49.2% 22.6% 28.2%
Table 1: Data set statistics, adverse drug event (AE) and sentiment scores.
Drug Drugs Drug Dose Drug Form Drug Effect Drug Property Que. Neg. Gen. Spec. Red.
2,320 216 615 51 2,845 1,037 137 360 313 169 308
Table 2: Occurrence counts for Phase 1 annotations (Que=Question, Neg=Negation, Gen=Generalisation, Spe=
Speculation, Red=ReducedCertainty; see Section 4.3).
Drug Effect and Drug Property annotations alto-
gether. 999 posts have at least one such annota-
tion; 258 posts have exactly 1, 197 have 2, 151
have 3, 108 have 4, and 285 have 5 or more (up to
28). Table 2 presents occurrence counts for enti-
ties and events from Phase 1.
6 Related Research
Structured information resources in health infor-
matics range from ordered lists of terms, glos-
saries and medical thesauri (MeSH5, UMLS (Bo-
denreider, 2004)), to ontologies like SNOMED
CT (Donnelly, 2006) and BioPax (Demir et al.,
2010). Such resources have underlying concept
models, from the very simple (e.g. in a drug list
each entry is a member of the class drug) to the
much more complex, e.g. ontologies incorporating
complex relations, properties and structures.
KE work in health informatics involves implicit
or explicit underlying concept models. Exam-
ples include adverse drug effect detection (Karimi
et al., 2015; Yates et al., 2015), usually involving
two main stages—entity identification and entity
linking—although some simply classify posts as
containing a drug-effect mention or not (Bollegala
et al., 2018). Others have applied further layers
of interpretation such as sentiment extraction, e.g.
headache is negative (Cameron et al., 2013).
Conceptualisations have been developed for
more complex health domains. Mowery et al. clas-
sify posts as containing evidence of depression to
5http://www.nlm.nih.gov/mesh/meshhome.html
yield a first layer of information which is then in-
stantiated by either a specific symptom or psy-
chosocial stressor (Mowery et al., 2015). Other
studies have addressed suicide (Desmet and Hoste,
2014; Huang et al., 2017), flu avoidance (Collier
et al., 2011), cyber-bullying (Van Hee et al., 2015),
and rumours (Zubiaga et al., 2016).
7 Conclusion
In this paper our aim has been to pin down and
clarify the interdependent and mutually constrain-
ing elements involved in developing an approach
to knowledge extraction, encompassing the under-
lying concept model, KE task construal and cor-
responding KE template, as well as the annotation
scheme. We have discussed the issues that arise
when addressing each of the elements, the choices
that need to be made and the trade-offs involved.
All this reflects our experience of developing an
annotation scheme for drug nonadherence. While
we have discussed the steps involved in develop-
ing a KE approach in the context of the nonadher-
ence domain, we found that many of the steps and
issues are not domain-specific, and are also appli-
cable to KE in other domains.
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